[go: up one dir, main page]

DK4240396T5 - Ifn-lambda-mrna til behandling af virusinfektioner - Google Patents

Ifn-lambda-mrna til behandling af virusinfektioner Download PDF

Info

Publication number
DK4240396T5
DK4240396T5 DK21805509.3T DK21805509T DK4240396T5 DK 4240396 T5 DK4240396 T5 DK 4240396T5 DK 21805509 T DK21805509 T DK 21805509T DK 4240396 T5 DK4240396 T5 DK 4240396T5
Authority
DK
Denmark
Prior art keywords
ifn
treatment
viral infections
lambda mrna
lambda
Prior art date
Application number
DK21805509.3T
Other languages
English (en)
Other versions
DK4240396T3 (da
Inventor
Carsten Rudolph
Christian Plank
Anna Macht
Kristin Lohmer
Thomas Langenickel
Original Assignee
Ethris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris Gmbh filed Critical Ethris Gmbh
Application granted granted Critical
Publication of DK4240396T3 publication Critical patent/DK4240396T3/da
Publication of DK4240396T5 publication Critical patent/DK4240396T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK21805509.3T 2020-11-04 2021-11-04 Ifn-lambda-mrna til behandling af virusinfektioner DK4240396T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20205674 2020-11-04
PCT/EP2021/080658 WO2022096582A1 (en) 2020-11-04 2021-11-04 Use of ifn-lambda mrna for treating viral infections

Publications (2)

Publication Number Publication Date
DK4240396T3 DK4240396T3 (da) 2025-03-17
DK4240396T5 true DK4240396T5 (da) 2025-04-07

Family

ID=73059724

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21805509.3T DK4240396T5 (da) 2020-11-04 2021-11-04 Ifn-lambda-mrna til behandling af virusinfektioner

Country Status (15)

Country Link
US (2) US20240181011A1 (da)
EP (2) EP4553084A3 (da)
JP (1) JP2023548498A (da)
KR (1) KR20230104140A (da)
CN (2) CN120285155A (da)
AU (1) AU2021375281A1 (da)
CA (1) CA3196195A1 (da)
DK (1) DK4240396T5 (da)
ES (1) ES3018013T3 (da)
FI (1) FI4240396T3 (da)
IL (1) IL302689B1 (da)
MX (1) MX2023005302A (da)
PL (1) PL4240396T3 (da)
PT (1) PT4240396T (da)
WO (1) WO2022096582A1 (da)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2299429C (en) 1997-08-13 2010-04-20 Biontex Laboratories Gmbh New lipopolyamines,their preparation and the use thereof
GB0405634D0 (en) * 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
EP1922081B1 (en) * 2005-09-09 2012-08-15 Imperial Innovations Limited Interferon lambda therapy for treatment of respiratory diseases
FR2925491B1 (fr) 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
EP3165234B1 (de) * 2009-07-31 2019-04-03 ethris GmbH Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
EA036400B1 (ru) 2013-06-28 2020-11-06 Этрис Гмбх Композиции для введения рнк в клетки
KR102647743B1 (ko) * 2014-11-10 2024-03-14 에트리스 게엠베하 Bmp 인코딩 rna의 전달에 의한 골형성 유도
JP6912384B2 (ja) * 2015-04-22 2021-08-04 キュアバック アーゲー 癌疾患の処置のための、ｒｎａ含有組成物
CN109154001B (zh) 2016-03-31 2023-07-18 埃泽瑞斯公司 Utr序列
CN110337305A (zh) * 2017-02-28 2019-10-15 赛诺菲 治疗性rna

Also Published As

Publication number Publication date
MX2023005302A (es) 2023-05-25
JP2023548498A (ja) 2023-11-17
PT4240396T (pt) 2025-03-26
WO2022096582A1 (en) 2022-05-12
ES3018013T3 (en) 2025-05-14
KR20230104140A (ko) 2023-07-07
FI4240396T3 (fi) 2025-03-31
US20250319160A1 (en) 2025-10-16
CN117729930A (zh) 2024-03-19
PL4240396T3 (pl) 2025-04-22
EP4240396A1 (en) 2023-09-13
AU2021375281A1 (en) 2023-06-01
CA3196195A1 (en) 2022-05-12
DK4240396T3 (da) 2025-03-17
EP4553084A3 (en) 2025-11-26
EP4240396B1 (en) 2025-01-01
IL302689A (en) 2023-07-01
US20240181011A1 (en) 2024-06-06
EP4553084A2 (en) 2025-05-14
IL302689B1 (en) 2025-12-01
CN120285155A (zh) 2025-07-11

Similar Documents

Publication Publication Date Title
DK4204421T3 (da) Forbindelser og fremgangsmåder til behandling af virale infektioner
IL289655A (en) Compounds useful to treat influenza virus infections
DK3810581T3 (da) Krystalmodifikationer af odevixibat
DK3684377T3 (da) Fremgangsmåder til behandling af hepatitis-b-infektion
DK3597646T3 (da) Terapeutiske forbindelser egnede til den profylaktiske eller terapeutiske behandling af en hiv-virusinfektion
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3504210T3 (da) 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
EP4157272C0 (en) REMDESIVIR FOR THE TREATMENT OF VIRAL INFECTIONS
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3805220T3 (da) Polycykliske carbamoylpyridon-derivater til behandling af hiv
DK3891145T3 (da) Modulatorer af trex1
DK3807260T3 (da) Oprensning af nikotin
DK3820849T3 (da) Phenyl/pyridyl-nh-phenyl/pyridyl-derivater til behandling af rna-virusinfektion
DK3370723T3 (da) Behandling af hepatitis delta-virusinfektion
DK3274340T3 (da) Hæmmere af hepatitis c-viruspolymerase
DK3271016T3 (da) Medicinsk sammensætning til behandling af urinvejsinfektion (uvi)
EP4117657A4 (en) Viral inhibition
DK3738330T3 (da) Håndtering af identifikatorvalidering
DK3743064T3 (da) Behandling af proteinuri
DK3856213T3 (da) Fremgangsmåder til behandling af infektioner under anvendelse af bakterier
DK3833378T3 (da) Behandling af vorter
DK3866778T3 (da) Kombinationer af hæmmere af influenzavirusreplikation